Advertisement Porton Biopharma - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Porton Biopharma

Bio-Pharmaceutical Development and Manufacturing

Logo
WHITE PAPERS
PRODUCTS & SERVICES
Quick Contact Porton Biopharma
LATEST PRESS RELEASES
September 2, 2020

PBL’S Commitment to Erwinase® Supply and Quality

PBL is acutely aware of the importance of Erwinase® for children suffering from acute lymphoblastic leukaemia (ALL) and is committed...
pharmacuetical business review
April 16, 2020

Porton Biopharma Limited Licenses Erwinase® to Clinigen

Porton Biopharma Limited (PBL), the UK biopharmaceutical research, development and manufacturing company, announces that it has signed an exclusive, worldwide...
pharmacuetical business review


LATEST VIDEOS

Porton Biopharma

Porton Biopharma Limited (PBL) is a manufacturer and developer of biopharmaceutical products ranging from next-generation vaccines to cancer treatments.

Based in the UK, the company specialises in progressing drug products from initial concept and research and development (R&D), through the various stages of scale-up and process development to manufactured product at pilot-scale. This includes product characterisation, analytical method development, stability studies and process troubleshooting.

PBL provides manufacturing services for both native and recombinant therapeutic proteins. The company offers a high level of documentation, demonstrating process and product consistency.

Product development services and production platforms

PBL has extensive experience in the development, manufacturing and commercialisation of biopharmaceutical products, as well as analytical support such as protein analysis and enzymology.

The company presents microbial product manufacturers with a flexible service that translates research methods into repeatable production processes. Products are well-characterised and of high-quality.

Contract manufacturing and drug product development

PBL provides a wide range of product development services, including characterisation, analytical development, process troubleshooting and technology transfer.

PBL offers production services for a wide range of clinical materials, including low-volume, high-potency and toxic bacterial products. Development fermentation studies are offered in a range of production platforms, including Wave-bagâ„¢ and stirred tank bioreactors from <1l bench-top fermenters through to fermentation suites with four 15l and one 50l vessel for parallel development and scale-up. Cell harvesting by batch, continuous centrifugation and tangential flow filtration are also available.

PBL also performs translational development to help biopharmaceutical products progress to good manufacturing practice (GMP) manufacturing. It leverages the experience of having its own products on the market.

PBL’s biopharmaceutical products include the UK’s anthrax vaccine and a therapeutic treatment for acute lymphoblastic leukaemia (ALL) Erwinase®, which is licensed in 20 locations worldwide. The company’s state-of-the-art current GMP (cGMP) facilities are licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA), Pharmaceuticals and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA).

Analytical development for process reproducibility

PBL performs analytical services and process redevelopment to optimise production. Options include the introduction of disposable technology to process modification, as well as method analysis and quantification. These services ensure that techniques are fit-for-purpose using the expert knowledge of PBL’s regulatory and validation teams.

The company’s development group designs and adapts analytical techniques to demonstrate process reproducibility and product quality.

In addition, PBL works closely with start-up biotech firms and mid/large pharmaceutical organisations worldwide to offer manufacturing process troubleshooting. The company finds the root cause of any issues and implements tried and tested solutions. This vigilant service reduces production costs with reduced downtime.

About Porton Biopharma

Commercialised out of Public Health England on 1 April 2015, PBL provides development and manufacturing services for life-saving products.

The company uses extensive biopharmaceutical experience to produce biologics and perform characterisation and analytical validation. Products meet regulatory requirements, which PBL fully understands from licensing its own products.

To find out how PBL can help you move your research from the bench to the clinic, please contact them via the enquiry box.

Contact

Porton Biopharma Limited
Manor Farm Road
Porton Down
Salisbury
Wiltshire, SP4 0JG
United Kingdom

Email: business@portonbiopharma.com
Tel: +44 198 061 2100
URL: www.portonbiopharma.com

Quick Contact Porton Biopharma


Top Products from Porton Biopharma

Quick Contact Porton Biopharma
Quick Contact Porton Biopharma

PBL’S Commitment to Erwinase® Supply and Quality

PBL is acutely aware of the importance of Erwinase® for children suffering from acute lymphoblastic leukaemia (ALL) and is committed...
2nd September 2020

Porton Biopharma Limited Licenses Erwinase® to Clinigen

Porton Biopharma Limited (PBL), the UK biopharmaceutical research, development and manufacturing company, announces that it has signed an exclusive, worldwide...
16th April 2020

Porton Biopharma – Erwinase® Manufacturing Schedule

PBL continues to supply Erwinase® finished product batches on time.
21st February 2020

PBL Supports Winning iGEM Team

Congratulations to the team of students from Nottingham University who travelled to Boston USA to present their work at the...
21st November 2019

PBL Gains Approval to Advance Next-Generation Anthrax Vaccine to Phase 1 Clinical Trial

Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract (HHSN272201600045C) with the US...
22nd October 2019

PBL Attending Salisbury Jobs Fair

Porton Biopharma has announced that it will be attending the Salisbury Jobs fair to discuss what the company does and its...
29th March 2019

PBL Takes On Its First Apprentice

In advance of the National Apprenticeship Week taking place from 4-8 March, Porton Biopharma (PBL) is excited to announce that it...
28th February 2019

Porton Biopharma Appoints New Chair

Porton Biopharma Limited is very pleased to announce the appointment of new non-executive chair, Barry Clare. 
20th February 2019

Manufacturing Novel Medicines for Inflammatory Bowel Disease

Porton Biopharma (PBL) is one of the leading British biotechnology businesses that have obtained grant funding from Innovate UK to...
22nd November 2018

PBL Supports the Royal Society of Biology

Porton Biopharma is pleased to be the official sponsor at the Royal Society of Biology’s President’s Dinner. 
1st May 2018

Porton Biopharma Opens New Facility to Make More Childhood Cancer Treatment

In a ribbon-cutting ceremony, member of parliament (MP) for Salisbury and South Wiltshire John Glen officially opened Porton Biopharma's (PBL)...
27th April 2018
Quick Contact Porton Biopharma


Quick Contact Porton Biopharma
Quick Contact Porton Biopharma
Quick Contact Porton Biopharma


Contact Porton Biopharma

Optional Data

Almost there, complete this form and hit the submit button to complete your registration.

Confirmation

Finally, complete a quick security check and confirm terms and conditions:

Quick Contact Porton Biopharma